Cover Image
市場調查報告書

B型F磷受體4:開發中產品分析

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 365798
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
B型F磷受體4:開發中產品分析 Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Pipeline Review, H1 2018
出版日期: 2018年01月31日 內容資訊: 英文 49 Pages
簡介

本報告提供以B型F磷受體4為標的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

B型F磷受體4 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 開發中的產品:各企業
  • 開發中的產品:各大學/機關

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Kadmon Corporation, LLC
  • VasGene Therapeutics, Inc.

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1278TDB

Summary:

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Ephrin type-B receptor 4 is a protein encoded by the EPHB4 gene. It binds promiscuously to transmembrane ephrin-B family ligands residing on adjacent cells which lead to contact dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. It plays a central role in heart morphogenesis and angiogenesis through regulation of cell adhesion and cell migration. It plays an important role in postnatal blood vessel remodeling, morphogenesis and permeability.

Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II stages are 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Genetic Disorders and Infectious Disease which include indications Non-Small Cell Lung Cancer, Recurrent Glioblastoma Multiforme (GBM), Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Colorectal Cancer, Gallbladder Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Kaposi Sarcoma, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Malignant Pleural Mesothelioma, Melanoma, Metastatic Brain Tumor, Myelodysplastic Syndrome, Pancreatic Cancer and Polycystic Kidney Disease.

The latest report Ephrin Type B Receptor 4 - Pipeline Review, H1 2018, outlays comprehensive information on the Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1)
  • The report reviews Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Overview
    • Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    • Eisai Co Ltd
    • Kadmon Corp LLC
    • VasGene Therapeutics Inc
  • Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Drug Profiles
    • golvatinib tartrate + lenvatinib mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit EphB4 Tyrosine Kinase for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Antagonize EphB4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Antagonize EphB4 Receptor for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tesevatinib tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vas-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VDAU-11 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Dormant Products
  • Ephrin Type B Receptor 4 (Hepatoma Transmembrane Kinase or Tyrosine Protein Kinase TYRO11 or EPHB4 or EC 2.7.10.1) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 13, 2017: Kadmon Initiates Phase 2 Placebo-Controlled Clinical Trial of Tesevatinib in Autosomal Dominant Polycystic Kidney Disease
      • Aug 07, 2017: FDA Grants Orphan Drug Designation to Kadmon's Tesevatinib for the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
      • Dec 06, 2016: Kadmon Presents Encouraging Data on Tesevatinib in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases and/or Leptomeningeal Metastases
      • Nov 19, 2016: Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016
      • Aug 29, 2016: Kadmon Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Glioblastoma
      • Dec 18, 2015: Kadmon Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Non-Small Cell Lung Cancer with Activating EGFR Mutations and Brain Metastases or Leptomeningeal Disease
      • Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015
      • May 28, 2015: Kadmon Announces Initial Phase 1b Data for Tesevatinib in Patients With Metastatic Breast Cancer
      • Apr 20, 2015: Kadmon Presents Encouraging Nonclinical Data on Tesevatinib (KD019) at AACR Annual Meeting
      • Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease
      • Jun 04, 2014: Kadmon Announces the Initiation of a Phase 1b/2a Study of KD019 and Trastuzumab in HER2-Positive Metastatic Breast Cancer
      • Apr 07, 2014: Kadmon Presents Preclinical Results Demonstrating KD019 Activity in Trastuzumab Resistant HER2+ Breast Cancer
      • Oct 24, 2012: Kadmon Doses First Patient In Phase Ib/IIa Study Of KD020 In Polycystic Kidney Disease
      • Feb 27, 2012: Biodesix Collaborates With Kadmon For Phase III Clinical Trial Of KD019
      • Oct 30, 2009: Eisai And Quintiles Enter Into A Strategic Collaboration To Develop Eisai's Anticancer Compounds
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Eisai Co Ltd, H1 2018
  • Pipeline by Kadmon Corp LLC, H1 2018
  • Pipeline by VasGene Therapeutics Inc, H1 2018
  • Dormant Projects, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top